TD Cowen raised the firm’s price target on Gilead (GILD) to $100 from $95 and keeps a Buy rating on the shares. The firm said they posted a ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Gilead said its fourth-quarter HIV product sales rose to $5.45 billion from $4.69 billion a year earlier, due to higher ...

A new rule requires insurers to improve coverage of PrEP, which can prevent HIV, but Georgians face challenges getting the ...

Gilead KOA Holiday has been recognized with the prestigious KOA ICON Award. This recognition highlights campgrounds that demonstrate exceptional operational excellence, customer satisfaction, and a ...

Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing. Gilead had reached an inflection point ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 26.8% in the past six months against the industry’s ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the bioscience giant for allegedly using joint research to develop an ...

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...